Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYD985 in HER2-expressing recurrent, advanced or metastatic endometrial carcinoma
2019-002888-10Phase 2Completed
- Sponsor
- Byondis
- Start
- Jan 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab duocarmazine in endometrial cancer (EC), sponsored by Byondis. Primary endpoint: Objective response rate. Started Jan 2020; status: completed.
02
Drugs
trastuzumab duocarmazine
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2019-002888-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002888-10.